Published in Health and Medicine Week, February 20th, 2006
This trial is designed to explore a new schedule of delivery with PX-12 given as a 24-hour infusion every 2 weeks, evaluating its safety, pharmacokinetic profile, and antitumor activity. The study will be conducted by Dr. Tomislav Dragovich at the Arizona Cancer Center in Tucson, Arizona.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.